Alkermes PLC (ALKS) Shares Sold by ProShare Advisors LLC
ProShare Advisors LLC lowered its position in Alkermes PLC (NASDAQ:ALKS) by 15.1% during the third quarter, Holdings Channel reports. The institutional investor owned 99,753 shares of the company’s stock after selling 17,781 shares during the period. ProShare Advisors LLC owned about 0.07% of Alkermes PLC worth $4,691,000 as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. BlackRock Advisors LLC raised its stake in Alkermes PLC by 0.3% in the third quarter. BlackRock Advisors LLC now owns 542,703 shares of the company’s stock worth $25,523,000 after buying an additional 1,595 shares in the last quarter. Wells Fargo & Company MN raised its stake in Alkermes PLC by 6.4% in the third quarter. Wells Fargo & Company MN now owns 260,694 shares of the company’s stock worth $12,261,000 after buying an additional 15,599 shares in the last quarter. BlackRock Japan Co. Ltd raised its stake in Alkermes PLC by 1.3% in the third quarter. BlackRock Japan Co. Ltd now owns 184,410 shares of the company’s stock worth $8,673,000 after buying an additional 2,341 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in Alkermes PLC by 1.9% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 3,942,795 shares of the company’s stock worth $185,430,000 after buying an additional 73,451 shares in the last quarter. Finally, Sei Investments Co. raised its stake in Alkermes PLC by 1,223.7% in the third quarter. Sei Investments Co. now owns 88,225 shares of the company’s stock worth $4,150,000 after buying an additional 81,560 shares in the last quarter. 95.88% of the stock is currently owned by institutional investors.
Alkermes PLC (NASDAQ:ALKS) traded up 2.69% on Friday, reaching $56.12. The company’s stock had a trading volume of 276,467 shares. The firm’s 50-day moving average price is $56.95 and its 200 day moving average price is $50.26. The company’s market cap is $8.53 billion. Alkermes PLC has a 52-week low of $27.14 and a 52-week high of $69.65.
Alkermes PLC (NASDAQ:ALKS) last released its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by $0.03. Alkermes PLC had a negative net margin of 36.92% and a negative return on equity of 12.75%. The company earned $180.20 million during the quarter, compared to the consensus estimate of $186.39 million. During the same quarter last year, the firm posted ($0.19) EPS. The company’s quarterly revenue was up 18.0% on a year-over-year basis. Equities analysts anticipate that Alkermes PLC will post ($0.20) EPS for the current fiscal year.
WARNING: “Alkermes PLC (ALKS) Shares Sold by ProShare Advisors LLC” was originally published by Daily Political and is owned by of Daily Political. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this article can be read at http://www.dailypolitical.com/2017/01/13/alkermes-plc-alks-shares-sold-by-proshare-advisors-llc.html.
ALKS has been the topic of a number of research analyst reports. Cowen and Company reaffirmed a “buy” rating on shares of Alkermes PLC in a research report on Friday, September 23rd. Citigroup Inc. raised their price target on Alkermes PLC from $44.00 to $53.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 27th. Zacks Investment Research lowered Alkermes PLC from a “hold” rating to a “sell” rating in a research report on Friday, October 14th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $52.00 price target on shares of Alkermes PLC in a research report on Wednesday, December 21st. Finally, Jefferies Group reaffirmed a “buy” rating and set a $70.00 price target on shares of Alkermes PLC in a research report on Thursday, November 17th. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Alkermes PLC has a consensus rating of “Buy” and a consensus price target of $60.83.
In related news, insider Shane Cooke sold 9,450 shares of the company’s stock in a transaction dated Friday, January 6th. The stock was sold at an average price of $60.06, for a total transaction of $567,567.00. Following the sale, the insider now owns 66,487 shares in the company, valued at approximately $3,993,209.22. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Mark Stejbach sold 547 shares of the company’s stock in a transaction dated Monday, January 9th. The shares were sold at an average price of $60.27, for a total value of $32,967.69. Following the sale, the senior vice president now owns 34,662 shares in the company, valued at approximately $2,089,078.74. The disclosure for this sale can be found here. 4.75% of the stock is owned by company insiders.
About Alkermes PLC
Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis.
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes PLC (NASDAQ:ALKS).
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.